CStone Pharmaceuticals Receives NMPA Approval for Domestic Production Transfer of Pralsetinib Capsules

1 week ago / Read about 0 minute

Author：小编

CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its drug registration application for the transfer of pralsetinib capsules from overseas production to domestic production. This approval marks a significant milestone, with the anticipation that, beginning in 2026, the supply of pralsetinib capsules in the Chinese mainland market will transition from imports to locally produced products. Pralsetinib capsules, a selective RET inhibitor, are indicated for the treatment of RET gene fusion-positive metastatic non-small cell lung cancer.

Previous page："Danas" Persists in Bringing Heavy Rainfall to the...

Next page：Domestic Futures Market Shows Predominantly Positi...

Return to List

Hot Reading

2 day ago

Study finds AI tools made open source software developers 19 percent slower

2 day ago

ByteDance's Mixed Reality Headset Now Under Development from Pico—Report

2 day ago

These Strange Jobs Will Survive AI, Expert Says

2 day ago

BYD has caught up with Tesla in the global EV race. Here’s how.